This study aims to investigate the benefit and feasibility of providing pharmacogenetic (PGx) testing as part of a standard medication therapy management (MTM) session for patients taking multiple medications, a high-risk population for adverse drug reactions and non-response. Research participants will attend two MTM sessions and undergo PGx testing to inform the MTM plan. Participants will also complete 2 surveys pre and post-MTM/PGx testing. Data analysis will assess the impact of MTM/PGx testing on recommendations for drug dosing, clinical outcomes, patient satisfaction, and feasibility of service delivery. Safety issues are minimal with the primary risks being associated with loss of confidentiality, typical discomfort associated with acquiring blood samples, and genetic discrimination.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
30
Patients will attend MTM sessions and receive PGx testing
Duke Health Center at Southpoint
Durham, North Carolina, United States
Patient satisfaction with MTM and PGx
This will be assessed by a quantitative survey
Time frame: 3 months after completion of MTM2
Change in clinical biomarkers associated with drug therapy
Changes in biomarkers before and after MTM/PGx will be measured. Biomarkers of study group will be compared to chart-review control
Time frame: baseline and 2 months
Number of recommended drug selection/dosing adjustments
Drug selection/doing changes will be compared between study population and chart-review controls
Time frame: approximately 9 months
Physician time to perform MTM and PGx
Time frame: end of study, approx. 9 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.